Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M. Llovet, Peiguo Cao, Philippe Merle et al.|The Lancet Oncology|2023Cited by 436